ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system.
Suqi Zeng et al.PubMed ↗Publisher ↗
No numbers read from the abstract.